Undergraduate of College of Basic Medicine, Hebei Medical University, Shijiazhuang, China.
Department of Nutrition and Food Hygiene, School of Public Health, Hebei Medical University, Hebei Province Key Laboratory of Environment and Human Health, Shijiazhuang, China.
Front Endocrinol (Lausanne). 2022 Mar 4;13:842152. doi: 10.3389/fendo.2022.842152. eCollection 2022.
Sesamin, the main lignin constituent of sesame, plays a pivotal role in regulating physical state. Some studies have evidenced that the supplementation of sesamin may decrease cardiovascular disease risk. The goal of this systematic review was to summarize evidence of the effects of sesamin supplementation on obesity, blood pressure, and lipid profile in humans by performing a meta-analysis of randomized controlled trials.
Five databases (PubMed, Cochrane Library, EMBASE, Web of Science, and Scopus) were searched electronically from inception to July 2021 to identify randomized controlled trials that assessed the impact of sesamin on obesity, blood pressure, and lipid profile. Weighted mean difference (WMD) and standard deviation (SD) were used to present the major outcomes.
Seven trials (n = 212 participants) were included in the overall analysis. Results showed that sesamin supplementation caused a great reduction in TC (WMD: -10.893 mg/dl, 95% CI: -19.745 to -2.041, p = 0.016), LDL-c (WMD: -8.429 mg/dl, 95% CI: -16.086 to -0.771, p = 0.031), and SBP (WMD: -3.662 mmHg, 95% CI: -6.220 to -1.105, p = 0.005), whereas it had no effect on HDL-c, TG, DBP, or weight. Subgroup analysis showed that duration, parallel design, and unhealthy status can affect TC, LDL-c, and SBP evidently. We did not discover a strong link between indicators' changes and duration of supplementation. Sesamin can be used as an obtainable dietary supplement to improve blood pressure and blood lipids, and further as a health product to prevent cardiovascular diseases.
芝麻素是芝麻中的主要木质素成分，在调节身体状态方面发挥着关键作用。一些研究表明，芝麻素的补充可能降低心血管疾病的风险。本系统评价的目的是通过对随机对照试验进行荟萃分析，总结芝麻素补充对人体肥胖、血压和血脂谱的影响的证据。
从研究开始到 2021 年 7 月，我们通过电子方式在 5 个数据库（PubMed、Cochrane Library、EMBASE、Web of Science 和 Scopus）中搜索随机对照试验，以评估芝麻素对肥胖、血压和血脂谱的影响。使用加权均数差（WMD）和标准差（SD）来表示主要结果。
共有 7 项试验（n = 212 名参与者）纳入总体分析。结果表明，芝麻素补充剂可显著降低 TC（WMD：-10.893mg/dl，95%CI：-19.745 至-2.041，p = 0.016）、LDL-c（WMD：-8.429mg/dl，95%CI：-16.086 至-0.771，p = 0.031）和 SBP（WMD：-3.662mmHg，95%CI：-6.220 至-1.105，p = 0.005），但对 HDL-c、TG、DBP 或体重没有影响。亚组分析表明，持续时间、平行设计和不健康状态可明显影响 TC、LDL-c 和 SBP。我们未发现指标变化与补充持续时间之间存在强烈关联。芝麻素可作为一种可获得的膳食补充剂，改善血压和血脂，进一步作为预防心血管疾病的保健品。
